40.78 USD
-1.27 (-3.02%)
40.78 USD
0 (0%)
Overall RIGL gets a fundamental rating of 7 out of 10. We evaluated RIGL against 531 industry peers in the Biotechnology industry. While RIGL has a great health rating, its profitability is only average at the moment. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make RIGL suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
RIGL had positive earnings in the past year.
RIGL had a positive operating cash flow in the past year.
RIGL had negative earnings in 4 of the past 5 years.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 46.72%, RIGL belongs to the top of the industry, outperforming 99.25% of the companies in the same industry.
RIGL has a better Return On Equity (96.34%) than 99.44% of its industry peers.
The Return On Invested Capital of RIGL (63.44%) is better than 99.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RIGL's Profit Margin of 40.17% is amongst the best of the industry. RIGL outperforms 96.80% of its industry peers.
The Operating Margin of RIGL (42.17%) is better than 98.68% of its industry peers.
RIGL has a Gross Margin of 93.10%. This is amongst the best in the industry. RIGL outperforms 93.60% of its industry peers.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
The number of shares outstanding for RIGL has been increased compared to 1 year ago.
Compared to 5 years ago, RIGL has less shares outstanding
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
RIGL has an Altman-Z score of -0.41. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
RIGL has a Altman-Z score of -0.41. This is comparable to the rest of the industry: RIGL outperforms 56.87% of its industry peers.
The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
RIGL's Debt to FCF ratio of 0.88 is amongst the best of the industry. RIGL outperforms 93.79% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
RIGL's Debt to Equity ratio of 0.25 is on the low side compared to the rest of the industry. RIGL is outperformed by 68.17% of its industry peers.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.41 |
ROIC/WACC7.12
WACC8.91%
2.3 Liquidity
RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL has a Current ratio of 2.28. This is in the lower half of the industry: RIGL underperforms 74.01% of its industry peers.
A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
RIGL's Quick ratio of 2.14 is on the low side compared to the rest of the industry. RIGL is outperformed by 73.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4307.14%, which is quite impressive.
The Revenue has grown by 79.13% in the past year. This is a very strong growth!
Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 36.89% on average per year.
The Revenue is expected to grow by 15.70% on average over the next years. This is quite good.
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.61, the valuation of RIGL can be described as very cheap.
98.68% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.54. RIGL is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 9.27, which indicates a very decent valuation of RIGL.
RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.68% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.78. RIGL is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 9.27 |
4.2 Price Multiples
RIGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.87% of the companies in the same industry.
97.74% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.86 | ||
| EV/EBITDA | 4.92 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as RIGL's earnings are expected to grow with 80.91% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y116.3%
EPS Next 3Y80.91%
5. Dividend
5.1 Amount
No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
40.78
-1.27 (-3.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.02%
Inst Owner Change8.17%
Ins Owners2.55%
Ins Owner Change0%
Market Cap740.16M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target46.24 (13.39%)
Short Float %17.6%
Short Ratio4.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)18.26%
PT rev (3m)18.26%
EPS NQ rev (1m)13.05%
EPS NQ rev (3m)42.6%
EPS NY rev (1m)17.94%
EPS NY rev (3m)17.94%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)3.5%
Revenue NY rev (3m)3.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 9.27 | ||
| P/S | 2.62 | ||
| P/FCF | 10.86 | ||
| P/OCF | 10.86 | ||
| P/B | 6.29 | ||
| P/tB | 8.02 | ||
| EV/EBITDA | 4.92 |
EPS(TTM)6.17
EY15.13%
EPS(NY)4.4
Fwd EY10.78%
FCF(TTM)3.75
FCFY9.21%
OCF(TTM)3.76
OCFY9.21%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.41 |
F-Score7
WACC8.91%
ROIC/WACC7.12
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year525.53%
EBIT Next 3Y109.33%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 611.29% in the next year.